Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Periodontology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 4 · 50%Very low 0 · 0%Low 4 · 50%Moderate 0 · 0%High 0 · 0%

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

Aesthetics · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

Enamel matrix derivative (EMD; Emdogain) showed no clear difference in aesthetics compared with placebo or control (same surgical or non-surgical intervention… (low certainty).

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
MD 1.0 [-5.4, 7.4]
1 study · 166 participants
Low

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

Change in gingival recession (REC) · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

Enamel matrix derivative (EMD; Emdogain) showed no clear difference in change in gingival recession (REC) compared with placebo or control (same surgical or non-surgical intervention… (low certainty).

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
MD 0.02 [-0.3, 0.3]
6 studies · 302 participants
Low

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

Marginal bone level change · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
No statistically significant difference between EMD and control for radiographic bone gain (three trials; P effect = 0.27, I2 = 78%).
3 studies
GRADE not reported

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

Change in probing pocket depth (PPD) · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

Enamel matrix derivative (EMD; Emdogain) may leads to higher change in probing pocket depth (PPD) compared with placebo or control (same surgical or non-surgical intervention… (low certainty).

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
MD 0.88 [0.44, 1.31]
9 studies · 371 participants
Low

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

Change in probing attachment level (PAL) · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

Enamel matrix derivative (EMD; Emdogain) may leads to higher change in probing attachment level (PAL) compared with placebo or control (same surgical or non-surgical intervention… (low certainty).

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
MD 1.08 [0.61, 1.55]
9 studies · 371 participants
Low

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

Tooth loss · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
SoF (Emdogain vs Control): Tooth loss - See comment / See comment; too few teeth lost to undertake analysis. 371 participants (9 studies). No GRADE rating given.
9 studies · 371 participants
GRADE not reported

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

Postoperative complications (infection) / adverse events · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
No particular adverse events or infection attributable to EMD in any trial; no differences in pain, edema, hematoma, wound dehiscence or root sensitivity (Tonetti 2002).
9 studies
GRADE not reported

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

PAL gain < 2 mm (dichotomous) · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

Enamel matrix derivative (EMD; Emdogain) led to lower PAL gain < 2 mm (dichotomous) compared with placebo or control (same surgical or non-surgical intervention…; GRADE not reported.

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
RR 0.53 [0.34, 0.82]
6 studies
GRADE not reported